Second-quarter profit was dented by a rise in expenses and sales of cancer drugs Enhertu and Imfinzi were slightly softer than expected, analysts said
raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its cancer, rare disease and heart disease medicines.
The shares slipped by as much as 4%. They were down 2.4% at 1000 GMT after gains of about 14% so far this year. But on Thursday they were one of the worst performers in the European pharma sector, which was down 0.14%. The UK’s most valuable company in terms of its market capitalization of 189.4 billion pounds has evolved significantly since CEO Pascal Soriot took over 12 years ago. New technologies such as antibody-drug conjugates are making up a rising proportion of its future cancer therapies.
Disease Share Astrazeneca Percentage Company Cancer Growth GSK Qingdao Astrazeneca
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Netflix is doubling down on India as its competitors back awayIndia brought in the second-highest net subscriber additions for Netflix in the second quarter.
Read more »
Downbeat Bank of Canada business and consumer surveys raise odds of second rate cutQuarterly survey found businesses expect the Canadian economy to remain in the doldrums and inflation to continue to decline
Read more »
Iffrig goes deep in Border Cats win over La CrosseThunder Bay wins for the second time in three second-half outings, downing the Loggers 7-3 in the second-last game of their current eight-game homestand.
Read more »
80 Cats Who Got A Second Chance At Life And Their Amazing Transformations (New Pics)We’ve gathered some wholesome and heartwarming before and after pics of cats who found their forever home.
Read more »
Milei Shifts Policy in Second Phase of Argentina Plan(Bloomberg) -- Argentine President Javier Milei’s administration embarked on what it called the second phase of its economic plan Friday by announcing that...
Read more »
Neuralink Surgery Postponed for Brain-Implant Startup’s Second PatientThe procedure to implant company’s technology was halted due to the patient’s medical condition
Read more »